» Articles » PMID: 30423048

Microbiological Diagnostic Performance of Metagenomic Next-generation Sequencing When Applied to Clinical Practice

Overview
Journal Clin Infect Dis
Date 2018 Nov 14
PMID 30423048
Citations 432
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Metagenomic next-generation sequencing (mNGS) was suggested to potentially replace traditional microbiological methodology because of its comprehensiveness. However, clinical experience with application of the test is relatively limited.

Methods: From April 2017 to December 2017, 511 specimens were collected, and their retrospective diagnoses were classified into infectious disease (347 [67.9%]), noninfectious disease (119 [23.3%]), and unknown cases (45 [8.8%]). The diagnostic performance of pathogens was compared between mNGS and culture. The effect of antibiotic exposure on detection rate was also assessed.

Results: The sensitivity and specificity of mNGS for diagnosing infectious disease were 50.7% and 85.7%, respectively, and these values outperformed those of culture, especially for Mycobacterium tuberculosis (odds ratio [OR], 4 [95% confidence interval {CI}, 1.7-10.8]; P < .01), viruses (mNGS only; P < .01), anaerobes (OR, ∞ [95% CI, 1.71-∞]; P < .01) and fungi (OR, 4.0 [95% CI, 1.6-10.3]; P < .01). Importantly, for mNGS-positive cases where the conventional method was inconclusive, 43 (61%) cases led to diagnosis modification, and 41 (58%) cases were not covered by empirical antibiotics. For cases where viruses were identified, broad-spectrum antibiotics were commonly administered (14/27), and 10 of 27 of these cases were suspected to be inappropriate. Interestingly, the sensitivity of mNGS was superior to that of culture (52.5% vs 34.2%; P < .01) in cases with, but not without, antibiotic exposure.

Conclusions: mNGS could yield a higher sensitivity for pathogen identification and is less affected by prior antibiotic exposure, thereby emerging as a promising technology for detecting infectious diseases.

Citing Articles

Antimicrobial strategies of lower respiratory tract infections in immunocompromised patients based on metagenomic next-generation sequencing: a retrospective study.

Meng B, Liu H, Wu Q, Qu L, Mao C, Yang F BMC Infect Dis. 2025; 25(1):360.

PMID: 40087607 DOI: 10.1186/s12879-025-10753-5.


Prevalence of bacteria, fungi, and virus coinfections with SARS-CoV-2 Omicron variant among patients with severe COVID-19 in Guangzhou, China, winter 2022.

Fan Q, Jiang M, Zhang J, Tang G, Gao M, Wen Y Biosaf Health. 2025; 6(2):92-97.

PMID: 40078947 PMC: 11895009. DOI: 10.1016/j.bsheal.2024.02.003.


mNGS-based dynamic pathogen monitoring for accurate diagnosis and treatment of severe pneumonia caused by fungal infections.

Li Z, Wu C, Tang L, Liang Y, A R, Huang D Biosaf Health. 2025; 5(3):138-143.

PMID: 40078515 PMC: 11895042. DOI: 10.1016/j.bsheal.2023.04.004.


Microbiological Diagnostic Performance and Clinical Effect of Metagenomic Next-Generation Sequencing for the Detection of Immunocompromised Patients With Community-Acquired Pneumonia.

Zheng H, Peng P, Wang S, Zhang B, Yang L, Wang Y Infect Drug Resist. 2025; 18:1223-1236.

PMID: 40052063 PMC: 11883178. DOI: 10.2147/IDR.S462358.


Clinical utility of nanopore-targeted sequencing for diagnosing and treating pulmonary infectious diseases from bronchoalveolar lavage fluid.

Li G, Sun H, Ye Y, Chen L, Zhang W, Yu S Front Cell Infect Microbiol. 2025; 15:1469440.

PMID: 40046190 PMC: 11879936. DOI: 10.3389/fcimb.2025.1469440.